Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 17/20 | 0.95 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL167772 | 1.00 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973509 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL192828 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7831398 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1268401 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1268399 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1130855 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7751943 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5974480 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7749172 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114306626-A | Allan phosphonic acid modified astragaloside IV PEG-PLGA nano micelle and research on anti-osteoporosis effect thereof | 席焱海 | 2022-04-12 | — | — | CN | claimed |
| EP-4746914-A1 | DRUG CONJUGATES FOR BONE MARROW PROTECTION | Zymeron Corporation (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250127799-A1 | DRUG CONJUGATES FOR BONE MARROW PROTECTION | UNITED STATES GOVERNMENT | 2025-04-24 | — | — | US | disclosed |
| WO-2025019691-A1 | DRUG CONJUGATES FOR BONE MARROW PROTECTION | Zymeron Corporation (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-3377549-B1 | PROLIFEROUS POLYMERS COMPRISING LACTAMIC MOIETIES | ISP INVESTMENTS LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240066144-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-02-29 | — | — | US | disclosed |
| CN-114306626-A | Allan phosphonic acid modified astragaloside IV PEG-PLGA nano micelle and research on anti-osteoporosis effect thereof | 席焱海 | 2022-04-12 | — | — | CN | disclosed |
| CN-114306626-A | Allan phosphonic acid modified astragaloside IV PEG-PLGA nano micelle and research on anti-osteoporosis effect thereof | 席焱海 | 2022-04-12 | — | — | CN | disclosed |
| US-20220023450-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| US-10844154-B2 | Proliferous copolymers comprising lactamic moieties | ISP INVESTMENTS LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-20050112202-A1 | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it | LERNER E I (IL) | 2005-05-26 | — | — | US | disclosed |
| EP-1492508-A1 | CONTROLLED RELEASE DOSAGE FORMS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-01-05 | — | — | EP | disclosed |
| EP-1465606-A2 | DOSAGE FORM WITH A CORE TABLET OF ACTIVE INGREDIENT SHEATHED IN A COMPRESSED ANNULAR BODY OF POWDER OR GRANULAR MATERIAL, AND PROCESS AND TOOLING FOR PRODUCING IT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-13 | — | — | EP | disclosed |
| US-20040087550-A1 | A bisphosphonate, carboxymethyl cellulose and xanthan gum viscosity agents, flavorants and purified water | GADOR, S.A. (AR) | 2004-05-06 | — | — | US | disclosed |
| US-20040052843-A1 | Controlled release dosage forms | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-03-18 | — | — | US | disclosed |
| EP-1372669-A1 | COMPOSITION COMPRISING BISPHOSPHONATES FOR PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES OF BONES, PROCESS FOR PREPARING SUCH COMPOSITION AND USE THEREOF | GADOR S.A. (AR) | 2004-01-02 | — | — | EP | disclosed |
| US-20030206954-A1 | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it | LERNER E ITZHAK (IL) | 2003-11-06 | — | — | US | disclosed |
| WO-2003075893-A1 | CONTROLLED RELEASE DOSAGE FORMS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003057136-A2 | DOSAGE FORM WITH A CORE TABLET OF ACTIVE INGREDIENT SHEATHED IN A COMPRESSED ANNULAR BODY OF POWDER OR GRANULAR MATERIAL, AND PROCESS AND TOOLING FOR PRODUCING IT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-07-17 | — | — | WO | disclosed |
| WO-2002058708-A1 | COMPOSITION COMPRISING BISPHOSPHONATES FOR PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES OF BONES, PROCESS FOR PREPARING SUCH COMPOSITION AND USE THEREOF | GADOR S.A. (AR) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023450-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | KIT, LIPA, CTSA | FDPS 3643/4885PDE3A 4601/4885LMNA 145/4885 |
| US-20250127799-A1 | DRUG CONJUGATES FOR BONE MARROW PROTECTION | MCL1, BST2, HCLS1 | FDPS 3539/4885PDE3A 4547/4885LMNA 2549/4885 |
| US-10844154-B2 | Proliferous copolymers comprising lactamic moieties | PCNA, MKI67, CCNA1 | FDPS 497/4885PDE3A 4439/4885LMNA 1224/4885 |
| US-20240066144-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | BST2, LIPG, LDLR | FDPS 3713/4885PDE3A 3930/4885LMNA 2321/4885 |
| US-20040087550-A1 | A bisphosphonate, carboxymethyl cellulose and xanthan gum viscosity agents, flavorants and purified water | BPGM, SOST, COL2A1 | FDPS 154/4885PDE3A 275/4885LMNA 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.